Simvastatin and Nirmatrelvir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 4, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Simvastatin
Nirmatrelvir
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
These two medicines should not be taken at the same time. Nirmatrelvir comes packaged with ritonavir (the COVID-19 pill Paxlovid), and it strongly blocks the liver enzyme that normally breaks down your simvastatin. When that enzyme is blocked, simvastatin builds up to much higher levels in your body.
Too much simvastatin can cause serious muscle problems, including a rare but dangerous condition called rhabdomyolysis, where muscle tissue breaks down. That can lead to muscle pain, weakness, and kidney trouble.
The good news is your care team can easily plan around this. Do not change anything on your own. Just talk with your pharmacist or doctor so they can safely manage your statin during your COVID-19 treatment.
Contraindicated combination. Nirmatrelvir is coformulated with ritonavir, a potent CYP3A4 inhibitor. Simvastatin is a CYP3A4 substrate (and its active acid metabolite depends on that pathway), so inhibition markedly increases simvastatin systemic exposure (AUC/Cmax), raising the risk of myopathy and rhabdomyolysis.
- Direction: increased simvastatin effect/toxicity
- Evidence: theoretical, but mechanism is well established and labeling designates it contraindicated
- Management: Discontinue simvastatin at least 12 hours before starting nirmatrelvir/ritonavir, throughout the 5-day course, and for 5 days after. Consider an alternative COVID-19 therapy if withholding the statin is not reasonable.
- Monitor: muscle pain/weakness, CK if symptomatic.
What happens
Increased risk of myopathy or rhabdomyolysis
Interaction Deep Dive
Because of the risk of myopathy, including rhabdomyolysis, giving simvastatin together with nirmatrelvir/ritonavir is contraindicated. Simvastatin should be stopped no less than 12 hours before nirmatrelvir/ritonavir is started, throughout the 5-day course of nirmatrelvir/ritonavir, and for an additional 5 days once nirmatrelvir/ritonavir has been finished1. When it is not clinically reasonable to pause simvastatin for this period, an alternative concomitant medication or COVID-19 therapy should be considered2.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated simvastatin metabolism
How to manage this interaction
This combination is avoided, but it is very manageable with planning. Because a short statin holiday is usually safe, your care team typically handles this by pausing simvastatin around your COVID-19 course.
- Your team may have you stop simvastatin at least 12 hours before starting nirmatrelvir/ritonavir, keep it stopped during the 5-day treatment, and for 5 days after finishing.
- If pausing your statin is not appropriate, your team may choose a different COVID-19 treatment.
What you should do: Do not start, stop, or change either medicine on your own. Tell your prescriber and pharmacist you take simvastatin before starting Paxlovid, and report any muscle pain, tenderness, weakness, or dark urine right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Simvastatin and Nirmatrelvir together?
Simvastatin and nirmatrelvir/ritonavir (Paxlovid) should not be taken together because simvastatin can build up and cause serious muscle damage; your care team can safely pause your statin during and shortly after the COVID-19 course, so check with them before starting. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Simvastatin and Nirmatrelvir interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Simvastatin and Nirmatrelvir interaction managed?
This combination is avoided, but it is very manageable with planning. Because a short statin holiday is usually safe, your care team typically handles this by pausing simvastatin around your COVID-19 course. Your team may have you stop simvastatin at least 12 hours before starting nirmatrelvir/ritonavir, keep it stopped during the 5-day treatment, and for 5 days after finishing. If pausing your st… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Simvastatin or Nirmatrelvir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Pfizer Labs: Fact sheet for healthcare providers: Emergency Use Authorization for PAXLOVID(TM). US Food & Drug Administration (FDA). Silver Spring, MD. 2022.
- COVID-19 Treatment Guidelines Panel: Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health (NIH). Bethesda, MD. 2023.
Keep reading about Simvastatin
Keep reading about Nirmatrelvir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist